Plain-English translation of NCT06679101 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing whether a medication called , when combined with two other drugs ( and ), works better than another common three-drug combination for treating newly diagnosed multiple myeloma in people who are not candidates for stem cell transplant. Researchers want to know if this new combination can help patients live longer without their cancer getting worse and achieve deeper remissions.
Multiple myeloma is a serious blood cancer, and while stem cell transplant is an effective treatment for some patients, many people are too old or have other health conditions that make this procedure too risky. This trial exists to find a better treatment option for these patients who need effective therapy but cannot undergo transplant.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive one of two three-drug combinations. You will take your assigned medications on a regular schedule, likely visiting the clinic regularly for blood tests, disease monitoring, and check-ups. The study will continue until your cancer progresses, you experience unacceptable side effects, you decide to stop, or the study ends—whichever comes first. Your participation may last months to years depending on how well the treatment works for you.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States